Vision on the Horizon: Horizon Pharma acquires River Vision’s Thyroid Eye Disease mAb
Horizon Pharma has announced it will acquire River Vision Development Corp. and its fully human monoclonal antibody (mAb), teprotumumab (RV001).
Horizon Pharma has announced it will acquire River Vision Development Corp. and its fully human monoclonal antibody (mAb), teprotumumab (RV001).
Avantor has agreed to purchase independent laboratory product, supply chain and service provider VWR for approximately $6.4bn (€5.9bn), reflecting a share price of $33.25.
Takeda has teamed up with GammaDelta Therapeutics to develop novel T-cell-based therapies in a deal that includes an option to buy the year-old UK biotech.
Pfizer has upped its presence in the gene therapy space through collaboration with Sangamo Therapeutics on its programmes worth up to $720m.
Formycon says it is aiming to bring the first biosimilar of J&J’s immunology best-seller Stelara (ustekinumab) to market as early as 2023 in the US.